BioInnovation Institute (BII), a non-profit foundation incubating and accelerating world-class life science research, today announces that twelve new companies have entered its Venture Lab acceleration program for early-stage start-ups. The cohort is strategically aligned with BII’s focus on supporting innovative early-stage start-ups that can improve human and planetary health.
The 12-month Venture Lab program is designed to support start-up companies with business acceleration, scientific, and team development, and provides a founder-friendly convertible loan of EUR 500,000 (approximately 4M DKK) plus access to labs and offices at BII in Copenhagen. In becoming a part of the Venture Lab program, the early-stage companies also get an exclusive opportunity to apply for EUR 1.3M in follow-up funding through BII’s Venture House program.
The new companies BII has accepted into the Venture Lab program are:
Human Health
3Sonic improves patient care with 3D ultrasound technology leading to precise surgical cancer treatment
Proxi Biotech is disrupting the vicious cycle of recurrent bacterial infections using our novel vaccine platform technology
Akasi Pharma is inspired by nature to develop the next generation of non-opioid therapeutics to treat pain
Beech Biotech is making mother-only antibodies treating preeclampsia in the mother without affecting her baby
Incipiam Pharma is developing small molecule weight loss drugs that increase fat burning directly in the fat cells. The company is enabling insulin-sensitizing, lean mass-sparing high quality weight loss
Synuca Therapeutics is developing first-in-class innovative small molecule calcium modulators capable of slowing the progression of Parkinson’s disease
Gefjon Pharma is combatting the challenges of antimicrobial resistance and planetary health by providing a cost-effective platform technology.
Navira is pioneering precision delivery to empower life-changing gene therapies (fully financed by Francis Crick Institute as part of a collaboration with BII)
Xterna uses enhanced modified nucleic acids to engineer next-generation drug delivery solutions (fully financed by Francis Crick Institute as part of a collaboration with BII)
Planetary Health
NanoGuard Crop Solutions helps farmers globally by safeguarding their crops with targeted insect pest control
Gefjon Pharma is combatting the challenges of antimicrobial resistance and planetary health by providing a cost-effective platform technology.
Cerelixis’ ambition is to provide innovative solutions improving crop productivity for sustainable agriculture
microMiner is working to make the recycling process for EV-batteries sustainable by replacing polluting chemicals with organic adsorbents